C. Sumey

发表

Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse

Kelly E McKinnon, S. Sorrells, Ashleigh McBratney, 2021, NPJ genomic medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016, Journal for ImmunoTherapy of Cancer.

Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program

M. Mazurczak, S. Powell, R. Sticca, 2020, Surgery open science.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.

S. Ramalingam, D. King, M. Razaq, 2020 .

Adjuvant medical therapy for prostate cancer

T. Flaig, C. Sumey, 2011, Expert opinion on pharmacotherapy.

Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.

P. Thompson, K. Gold, E. Cohen, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

P. Bunn, W. Franklin, M. Varella‐Garcia, 2012, Cancer.

Longitudinal and multi-tissue molecular diagnostics track somatic BRCA2 reversion mutations that correct the open reading frame of germline alteration upon clinical relapse

C. Sumey, Kelly E. McKinnon, Shelly Sorrells, 2021, npj Genomic Medicine.

Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).

A. Armstrong, T. Dorff, L. Horvath, 2020 .

Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).

P. Thompson, K. Gold, E. Cohen, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Adjuvant medical therapy for prostate cancer

T. Flaig, C. Sumey, 2011, Expert opinion on pharmacotherapy.

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

D. Danila, L. Appleman, H. L. Penny, 2023, Cancer discovery.